Organon (OGN) EBITDA (2020 - 2026)

Organon's EBITDA history runs 7 years deep, the most recent figure standing at $235.0 million for Q1 2026.

• In Q1 2026, EBITDA fell 1.67% year-over-year to $235.0 million; the TTM figure through Mar 2026 stood at $1.1 billion (down 14.88% YoY), while the FY2025 annual figure was $1.1 billion, up 569.23% from the prior year.
• EBITDA was $235.0 million for Q1 2026 at Organon, up from $210.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $411.0 million in Q3 2024 to a low of -$579.0 million in Q4 2023.
• Historically, EBITDA has averaged -$58.4 million across 5 years, with a median of -$119.0 million in 2022.
• The sharpest annual moves came in 2023 and 2024: EBITDA sank 189.92% in 2023, then surged 200.0% in 2024.
• A 5-year view of EBITDA shows it stood at -$483.0 million in 2022, then fell by 19.88% to -$579.0 million in 2023, then surged by 149.74% to $288.0 million in 2024, then decreased by 27.08% to $210.0 million in 2025, then grew by 11.9% to $235.0 million in 2026.
• The last three EBITDA figures came in at $235.0 million (Q1 2026), $210.0 million (Q4 2025), and $358.0 million (Q3 2025), per Business Quant data.